Replimune Group Inc
REPL
NASDAQ
Biotechnology
$14.97
USD
-0.22 (-1.45%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.28B
Volume 2.4M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-313.94M
TTM
-26.9%
YoY
Operating Cash Flow
$-280.34M
TTM
-45.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 25.4 | 32.6 | 26.4 | 18.7 | 21.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 79.3 | 90.4 | 84.3 | 71.9 | 73.3 |
Operating Income | -79.3 | -90.4 | -84.3 | -71.9 | -73.3 |
EBITDA | -78.5 | -89.5 | -85.2 | -69.3 | -72.6 |
Other Income / Expense | 1.2 | 1.0 | -0.5 | -0.2 | 0.4 |
Total Other Income / Expense | 5.1 | 3.7 | 1.2 | 0.6 | -0.1 |
Income Before Income Taxes | -74.2 | -86.7 | -83.1 | -71.2 | -73.5 |
Income Taxes | -0.1 | 0.0 | 0.0 | -0.3 | -0.2 |
Net Income | -74.1 | -86.7 | -83.1 | -70.9 | -73.2 |
Consolidated Net Income / Loss | -74.1 | -86.7 | -83.1 | -70.9 | -73.2 |
Net Income Attributable to Common Shareholders | -74.1 | -86.7 | -83.1 | -70.9 | -73.2 |
Basic EPS | -$0.81 | -$0.95 | -$0.90 | -$0.77 | -$0.77 |
Diluted EPS | -$0.81 | -$0.95 | -$0.90 | -$0.77 | -$0.77 |
Basic Shares Outstanding | 91.0M | 91.5M | 91.9M | 92.2M | 95.6M |
Diluted Shares Outstanding | 91.0M | 91.5M | 91.9M | 92.2M | 95.6M |